Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31253801 | 0.87 | PLK1 (0.77) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL11962158 | 0.85 | PLK1 (1.00) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7921171 | 0.85 | PLK1 (0.74) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL12839873 | 0.85 | PLK1 (0.87) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL14880157 | 0.85 | PLK1 (0.73) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL2636457 | 0.85 | PLK1 (0.73) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13908659 | 0.84 | PLK1 (0.73) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL28912681 | 0.84 | PLK1 (0.72) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL14341662 | 0.83 | PLK1 (0.71) | PLK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL10294638 | 0.83 | RAB9A (0.75) | PLK1NPC1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | claimed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | claimed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | claimed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023288033-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-2696873-B1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200048249-A1 | PTPN11 INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-02-13 | — | — | US | disclosed |
| WO-2019032563-A1 | INHIBITORS OF BASE EXCISION REPAIR ACTIVITY AND THERAPEUTIC METHODS BASED THEREON | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | PLK1 2313/4885NPC1 87/4885RAB9A 3470/4885 |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | HDAC1, HDAC5, HDAC7 | PLK1 799/4885NPC1 3002/4885RAB9A 4295/4885 |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | PLK1, POLD1, CTDSP1 | PLK1 1/4885NPC1 4559/4885RAB9A 3398/4885 |
| US-20200048249-A1 | PTPN11 INHIBITORS | PTPRJ, PTPN11, PTPRF | PLK1 857/4885NPC1 2518/4885RAB9A 1141/4885 |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | OGG1, UNG, MPG | PLK1 1030/4885NPC1 3192/4885RAB9A 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.